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Hyperactivation of Wnt and Ras-MAPK signalling are common events in development of colorectal 
adenomas. Further progression from adenoma-to-carcinoma is frequently associated with 20q gain 
and overexpression of Aurora kinase A (AURKA). Interestingly, AURKA has been shown to further 
enhance Wnt and Ras-MAPK signalling. However, the molecular details of these interactions in driving 
colorectal carcinogenesis remain poorly understood. Here we first performed differential expression 
analysis (DEA) of AURKA knockdown in two colorectal cancer (CRC) cell lines with 20q gain and AURKA 
overexpression. Next, using an exact algorithm, Heinz, we computed the largest connected protein-
protein interaction (PPI) network module of significantly deregulated genes in the two CRC cell lines. 
The DEA and the Heinz analyses suggest 20 Wnt and Ras-MAPK signalling genes being deregulated by 
AURKA, whereof β-catenin and KRAS occurred in both cell lines. Finally, shortest path analysis over 
the PPI network revealed eight ‘connecting genes’ between AURKA and these Wnt and Ras-MAPK 
signalling genes, of which UBE2D1, DICER1, CDK6 and RACGAP1 occurred in both cell lines. This study, 
first, confirms that AURKA influences deregulation of Wnt and Ras-MAPK signalling genes, and second, 
suggests mechanisms in CRC cell lines describing these interactions.
Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in 
women worldwide1. In the early stages of CRC development, proliferative signalling is sustained by hyperactiva-
tion of the Wnt and Ras-MAPK signalling pathways due to mutations in key regulatory genes2. Disruption of Wnt 
signalling, caused by mutations in the APC tumour suppressor gene or other genes such as CTNNB1 (hereafter 
referred to as β-catenin), AXIN1 or AXIN2, promotes the progression from normal colon epithelium to a benign 
precursor lesion, called adenoma3. Subsequently, adenoma-to-carcinoma progression is driven by further genetic 
and epigenetic alterations. For example, in addition to the Ras-MAPK pathway, activated by mutation in e.g. the 
KRAS gene, other pathways important in carcinoma development are the TGFβ pathway, disrupted by mutation 
in e.g. SMAD4, and the TP53 pathway, disrupted by mutations in the TP53 gene4,5. Recently, it has been shown 
that adenoma organoids harbouring all these mutations can induce invasive cancers in mice only when a back-
ground of chromosomal instability is present6. This signifies the importance of chromosomal instability, which in 
fact occurs in ~85% of CRC7, and is characterized by gross chromosomal aberrations.
Chromosomal arm 20q is frequently gained in CRC8,9 and has a strong association with the progression of 
colorectal adenoma to carcinoma10. Aurora kinase A (AURKA), a gene coding for a key cell cycle regulator, is 
located on 20q. There is a significant correlation between the 20q copy number and increased AURKA mRNA 
1Centre for Integrative Bioinformatics (IBIVU), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 
2Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 3Department of 
Pathology, VU University Medical Center, Amsterdam, The Netherlands. 4Bioinformatics group at the NIHR 
Biomedical Research Centre for Mental Health (IOP) and the South London and Maudsley NHS Trust, London, UK. 
5The BRC Translational Bioinformatics Unit at the NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS 
Foundation Trust and King’s College London, London, UK. Correspondence and requests for materials should be 
addressed to K.A.F. (email: k.a.feenstra@vu.nl)
Received: 5 January 2018
Accepted: 12 April 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIeNTIFIC REPORTS |  (2018) 8:7522  | DOI:10.1038/s41598-018-24982-z
and protein expression11. Gain of 20q and/or AURKA overexpression is associated with a poor prognosis in many 
cancer types including CRC12–17.
AURKA overexpression has been shown to stabilize β-catenin levels and thereby activating Wnt signalling in 
gastric cancer cells by phosphorylating the negative regulator of β-catenin, GSK3B18,19. Also in glioma-initiating 
cells (distinguished by their capacity of self-renewal) AURKA is a negative regulator of β-catenin, by binding to 
AXIN120. Recently, it has been shown that AURKA upregulates Ras-MAPK signalling by interacting with the 
H-RAS/Raf-1 complex in kidney cells21. In addition, AURKA itself has been shown to be a target gene of both 
MAPK1/ERK2 signalling in pancreatic cancer cells22 and Wnt/β-catenin signalling in multiple myeloma23. These 
data suggest a positive feedback loop from hyperactive proliferative signalling to AURKA overexpression, further 
inducing proliferative signalling cells21.
All this implies that there is interplay between AURKA and the Wnt and Ras-MAPK signalling pathways and 
vice versa in different cancer settings. For Wnt and Ras-MAPK signalling, much of the mechanisms have been 
elucidated, also in relation with CRC24, but such detail is not available for the interplay with AURKA. Although 
different molecular mechanisms are observed in the different settings this argues that the regulation itself is 
important. In this study, we used two distinct cell lines, SW480 and Caco2, both derived from colon carcinomas 
with 20q copy number gain and mutated TP53. However, the genetics differ between these cell lines, they orig-
inate from different individuals and therefore have different germline variations, and they have progressed to 
carcinomas independently and therefore also differ in their somatic alterations, such as DNA mutations and DNA 
copy number alterations. The distinct DNA copy number profiles of the two cell lines are shown in Supplementary 
Fig. S1. Further, a comparative study of colon cancer cell lines showed that out of five critical cancer genes (KRAS, 
BRAF, PIK3CA, PTEN, and TP53) only the mutation status of KRAS differed between the two cell lines (mutated 
in SW480). Further, of the other four genes TP53 was mutated in both cell lines25. Using SW480 and Caco2, we 
set out to investigate which key players and molecular interactions are involved in the interplay between AURKA 
and the Wnt and Ras-MAPK pathways that may drive progression of CRC.
Results
Differentially mRNA expression analysis. Differential expression analysis (DEA) was performed upon 
AURKA siRNA-directed downmodulation in two CRC cell lines with 20q gain and AURKA overexpression, 
SW480 and Caco2. AURKA was the most differentially downregulated gene in both cell lines (p-value of 1.69e-6 in 
SW480 and 2.28e-7 in Caco2), indicating that the siRNA experiment was successful. The number of significantly 
expressed genes in response to AURKA downmodulation at a q-value less than 0.05 was 2,057 and 3,606 in SW480 
and Caco2, respectively. 924 genes were significantly deregulated in both cell lines, whereof 50 were deregulated 
in opposite directions. In our analysis, however, we applied a more stringent threshold to determine significantly 
deregulated genes including both a q-value less than 0.05 and a fold change greater than 1.5 or less than −1.5. This 
resulted in a 292 and 154 significantly deregulated genes in SW480 and Caco2, respectively. Of the 292 genes sig-
nificantly deregulated in SW480, 139 genes were upregulated and 153 downregulated (Fig. 1A and Supplementary 
Table S1). Of the 154 genes significantly deregulated in Caco2, 73 genes were upregulated and 81 downregulated 
(Fig. 1B and Supplementary Table S2). Fifty-four genes were significantly deregulated in both cell lines (Fig. 1C 
and Table 1). Fifty-three of these 54 were deregulated in the same direction in both cell lines: 28 up in both and 25 
down in both. The only gene deregulated in different directions was SLC12A2, which was up in Caco2 and down in 
SW480. These 53 genes are interesting candidates for the general influence of AURKA. GO enrichment analysis of 
these genes revealed that ‘mitotic cell cycle’ was the most significantly enriched process (Fig. 1D).
Identification of the most significantly deregulated gene modules. In order to gain understanding 
from the sets of genes differentially expressed by AURKA knockdown, we applied the Heinz algorithm26. Heinz 
integrates significant deregulation (the p-values from the DEA described above) with molecular protein inter-
action data (PPI network data from STRING)27. The algorithm looks for significantly deregulated gene modules 
(sets of genes connected in the PPI network), which might include genes that show no expression changes, based 
on the intuition that some regulatory effects may involve changes that are not visible at the expression level. The 
genes in these modules can therefore be considered ‘functionally’ deregulated. First, weights are assigned to each 
node reflecting its p-value from the DEA. The chosen FDR cut-off determines which nodes are assigned posi-
tive weights (p-value below threshold) or negative (above threshold). The Heinz algorithm then computes the 
most significantly deregulated gene module, which is based both on the connectivity of the PPI network and the 
assigned weights. By thus combining the differential expression and protein interaction data, we can identify the 
most significantly deregulated gene modules (or functionally deregulated genes) upon AURKA downmodulation.
The FDR threshold was set to 6.21e-4 for SW480 and 2.40e-4 for Caco2. These thresholds were selected so 
that only the 50 most significantly deregulated genes were assigned positive weights. This selection allowed us 
to focus this analysis on gene modules of interpretable sizes (see Materials and Methods for further details). 
Figure 2 shows the most significantly deregulated gene modules for SW480 and Caco2. For SW480 the most sig-
nificantly deregulated gene module consisted of 30 differentially expressed nodes (15 up and 15 down; see Fig. 2A 
and Supplementary Table S3). Twenty-three were significantly deregulated (positive weight, circles in Fig. 2A) 
and seven non-significant (negative weight, squares in Fig. 2A). For Caco2 the most significantly deregulated 
gene module consisted of 31 differentially expressed nodes (13 up and 18 down; see Fig. 2B and Supplementary 
Table S4). Twenty-nine were significantly deregulated (positive weight, circles in Fig. 2B) and two non-significant 
(negative weight, square in Fig. 2B. Note that remaining genes out of the 50 genes with positive weights do not 
occur in the largest connected module, because they are not connected in the PPI network. The intersection 
between the most significantly deregulated gene modules of each of the two cell lines contains nine genes: 
AURKA, β-catenin, HMMR, KRAS, MBNL1, NUP98, REEP5, TNFRSF11B and UBE2D1 (black outline in nodes 
in Fig. 2A,B). These are all directly connected in the modules (bold edges in Fig. 2A,B), except for MBNL1, which 
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is connected via one intermediate node: in SW480 via JUN to KRAS, β-catenin and TNFRSF11B, and in Caco2 via 
ALB to KRAS, AURKA, β-catenin and TNFRSF11B, and via FOS to KRAS, UBE2D1, β-catenin and TNFRSF11B.
This integrative approach, using the p-values from the DEA and the PPI network data from STRING deter-
mined 30 and 31 genes in the most significantly deregulated gene modules for SW480 and Caco2, respectively. 
This analysis identified three genes for SW480 (JUN, RPS3A and LCK) and two genes for Caco2 (β-catenin and 
FOS), which were not significantly deregulated in the DEA.
Proteins and interactions involved in enhanced Wnt and Ras-MAPK signalling by AURKA. We 
then set out to annotate Wnt and Ras-MAPK signalling genes that were either significantly deregulated in the 
gene-centric DEA or found in the most significantly deregulated gene modules in the integrative network-aware 
Heinz analysis. In total, 20 genes in either of these two signalling pathways were identified: four genes in the Wnt 
pathway (AXIN2, β-catenin, CTBP1 and WNT5A), eleven in the Ras-MAPK pathway (DDIT3, PDGFRA, RAP1B, 
KITLG, FOS, DUSP5, PLD1, KRAS, LAT, MAP3K6, RGL1), and five in both pathways (PRKCA, PPP3CA, RAC2, 
PPP3R1 and JUN) (see Fig. 3A). Two of these 20 deregulated genes, KRAS and β-catenin, appeared in both cell 
lines. The other 18 genes behaved cell line specific in these analyses: ten genes were found in SW480 only and 
eight genes were found only in Caco2 (Fig. 3A). When looking at Wnt and Ras-MAPK genes compared to all 
selected genes by the DEA (significantly deregulated) and the Heinz analysis (part of the most significantly dereg-
ulated gene module), respectively, we see different enrichments. For the DEA this was 11/292 (4%) and 8/154 
(5%) for SW480 and Caco2, respectively (coloured nodes in Fig. 3A, and totals in Fig. 1C). On the other hand, for 
the Heinz analysis this was 5/30 (17%) and 9/31 (29%) for SW480 and Caco2, respectively (black dots vs. all nodes 
in Fig. 2A,B). Hence, Wnt and Ras-MAPK signalling genes were much more enriched in the deregulated modules 
selected by the network-aware Heinz analysis compared to the DEA, suggesting that their mutual interaction 
within the associated PPI network modules is important for CRC progression.
Figure 1. Differential mRNA expression analysis of AURKA knockdown in SW480 (A) and Caco2 (B) 
colorectal cancer cell lines. (A) and (B) Volcano plot of all unique genes from the differential mRNA expression 
analysis upon AURKA downmodulation for the SW480 and Caco2 cell lines, respectively. The vertical and 
horizontal lines illustrate the boundaries between significantly downregulated genes (red dots), significantly 
upregulated genes (blue dots) and non-significant differential genes (black dots). Horizontal lines represent the 
significance threshold of the q-value < 0.05. Vertical lines represent the significance threshold of the fold change 
1.5 (log2 fold change 0.58) up or down. C) VENN diagram of the number of significantly deregulated genes in 
SW480 and Caco2 (see Table 1). D) GO enrichment of the genes (n = 53) that are significantly deregulated in 
both cell lines in the same direction (the intersection in the Venn diagram in C minus one gene).
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Gene ID Gene name
SW480 Caco2
p-value q-value FC** p-value q-value FC**
AURKA Aurora kinase A 1.69e-6 1.86e-2 −1.64 2.28e-7 1.96e-3 −1.31
REEP5 Receptor accessory protein 5 2.20e-5 1.86e-2 −1.24 1.83e-6 5.18e-3 −0.97
SLC12A2 Solute carrier family 12 member 2 5.70e-6 1.86e-2 −1.05 1.39e-5 6.82e-3 0.70
DICER1 Dicer 1, ribonuclease III 1.94e-4 2.35e-2 −1.02 6.79e-5 1.00e-2 −0.75
FEZ2 Fasciculation and elongation protein zeta 2 7.41e-6 1.86e-2 −0.99 7.61e-6 6.82e-3 −0.70
KRAS KRAS proto-oncogene, GTPase 9.58e-6 1.86e-2 −0.95 1.10e-5 6.82e-3 −0.65
UBE2D1 Ubiquitin conjugating enzyme E2 D1 3.08e-4 2.55e-2 −0.92 1.08e-5 6.82e-3 −0.91
TM4SF1 Transmembrane 4 L six family member 1 1.10e-4 2.28e-2 −0.91 2.03e-5 7.98e-3 −0.74
ACVR1 Activin A receptor type 1 2.60e-4 2.46e-2 −0.87 6.36e-6 6.82e-3 −0.99
MARVELD2 MARVEL domain containing 2 2.61e-5 1.86e-2 −0.87 2.13e-5 7.98e-3 −0.66
BORCS8 BLOC-1-related complex subunit 8 2.91e-5 1.86e-2 −0.86 1.61e-5 7.31e-3 −0.64
SLC25A24 Solute carrier family 25 member 24 5.87e-5 2.10e-2 −0.85 1.10e-5 6.82e-3 −0.71
MBOAT2 Membrane bound O-acyltransferase domain containing 2 1.73e-4 2.35e-2 −0.76 7.00e-6 6.82e-3 −0.84
ACOX2 Acyl-CoA oxidase 2 3.59e-5 1.86e-2 −0.74 2.78e-5 8.77e-3 −0.61
TNFRSF11B TNF receptor superfamily member 11b 3.13e-5 1.86e-2 −0.74 3.02e-7 1.96e-3 −1.18
NA* ENSG00000260912* 3.47e-3 4.91e-2 −0.74 4.04e-5 9.30e-3 −1.05
NA* ENSG00000234119* 3.74e-5 1.91e-2 −0.71 8.20e-6 6.82e-3 −0.69
SNX24 Sorting nexin 24 2.46e-3 4.32e-2 −0.70 5.16e-5 9.83e-3 −0.86
ANP32 A Acidic nuclear phosphoprotein 32 family member A 8.22e-5 2.26e-2 −0.70 2.15e-5 7.98e-3 −0.62
CANX Calnexin 5.44e-4 2.89e-2 −0.70 2.32e-6 5.52e-3 −0.95
TMX2P1 Thioredoxin related transmembrane protein 2 pseudogene 1 2.87e-4 2.49e-2 −0.70 5.42e-5 9.96e-3 −0.63
B4GALT4 Beta-1,4-galactosyltransferase 4 8.17e-4 3.19e-2 −0.68 3.53e-6 6.82e-3 −1.17
SNX4 Sorting Nexin 4 1.09e-4 2.28e-2 −0.67 4.74e-5 9.65e-3 −0.61
TSPYL4 TSPY like 4 1.41e-4 2.35e-2 −0.66 8.55e-6 6.82e-3 −0.71
PHLDA2 Pleckstrin homology like domain family A member 2 1.67e-3 3.74e-2 −0.60 4.19e-5 9.37e-3 −0.61
TP53I3 Tumor protein p53 inducible protein 3 1.31e-4 2.35e-2 −0.59 2.61e-5 8.77e-3 −0.60
ARHGAP19 Rho GTPase activating protein 19 2.25e-4 2.37e-2 0.59 7.93e-6 6.82e-3 0.74
LAMC1 Laminin subunit gamma 1 6.03e-4 2.95e-2 0.60 6.01e-6 6.82e-3 0.96
STK17B Serine/threonine kinase 17b 1.32e-3 3.54e-2 0.61 5.71e-5 1.00e-2 0.65
NRP2 Neuropilin 2 2.83e-3 4.55e-2 0.65 4.83e-5 9.65e-3 0.85
IDNK IDNK, gluconokinase 2.18e-3 4.17e-2 0.67 2.16e-4 1.34e-2 0.62
KTN1 Kinetin 1 4.50e-5 2.05e-2 0.68 1.88e-5 7.93e-3 0.60
RACGAP1 Rac GTPase activating protein 1 2.77e-4 2.49e-2 0.72 6.11e-5 1.00e-2 0.65
CDK6 Cyclin dependent kinase 6 8.63e-5 2.26e-2 0.75 4.60e-6 6.82e-3 0.86
SPA17 Sperm autoantigenic protein 17 1.51e-4 2.35e-2 0.77 2.00e-5 7.98e-3 0.66
LINC00467 Long intergenic non-protein coding RNA 467 3.30e-5 1.86e-2 0.80 8.62e-6 6.82e-3 0.68
BUB1B BUB1 mitotic checkpoint serine/threonine kinase B 3.99e-5 1.94e-2 0.83 1.84e-5 7.89e-3 0.70
BIK BCL2 interacting killer 3.11e-5 1.86e-2 0.86 2.01e-6 5.18e-3 0.87
SH3D19 SH3 domain containing 19 1.22e-4 2.35e-2 0.89 1.05e-5 6.82e-3 0.83
EIF4EBP2 Eukaryotic translation initiation factor 4E protein binding 2 7.50e-5 2.26e-2 0.92 2.09e-5 7.98e-3 0.72
HMMR Hyaluronan mediated motility receptor 4.07e-5 1.95e-2 0.95 1.17e-5 6.82e-3 0.74
KLHL15 Kelch like family member 15 3.55e-4 2.64e-2 0.95 2.46e-4 1.42e-2 0.59
DYRK2 Dual specificity tyrosine phosphorylation regulated kinase 2 4.09e-4 2.69e-2 0.97 3.68e-5 9.30e-3 0.80
ZNF268 Zink finger protein 268 3.95e-4 2.66e-2 0.98 8.72e-5 1.07e-2 0.67
NUP98 Nucleoporin 98 9.71e-6 1.86e-2 0.98 6.76e-6 6.82e-3 0.73
MTMR6 Myotubularin related protein 6 8.09e-4 3.19e-2 0.99 1.18e-4 1.20e-2 0.78
PTP4A1 Protein tyrosine phosphatase type IVA, member 1 5.08e-4 2.85e-2 1.04 1.94e-4 1.31e-2 0.80
GOLT1B Golgi transport 1B 1.36e-5 1.86e-2 1.04 1.95e-5 7.98e-3 0.63
RPS27L Ribosomal protein S27 like 6.91e-6 1.86e-2 1.05 1.06e-5 6.82e-3 0.67
MALAT1 Metastasis associated lung adenocarcinoma transcript 1 1.46e-3 3.66e-2 1.09 1.06e-5 6.82e-3 1.67
Continued
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The most significantly deregulated gene modules also suggest interactions between AURKA and the Wnt and 
Ras-MAPK pathway (Fig. 2). Only KRAS is directly connected to AURKA, whereas the other genes are indi-
rectly connected to AURKA via one or more genes. In order to identify interactions between AURKA and the 
remaining genes of the 20 Wnt and Ras-MAPK genes, we applied a shortest path analysis through the protein 
Gene ID Gene name
SW480 Caco2
p-value q-value FC** p-value q-value FC**
LAMP2 Lysosomal associated membrane protein 2 3.30e-4 2.62e-2 1.10 4.75e-5 9.65e-3 0.98
SYPL1 Synaptophysin like 1 5.69e-6 1.86e-2 1.11 5.63e-6 6.82e-3 0.73
ARRDC4 Arrestin domain containing 4 1.55e-3 3.70e-2 1.24 2.11e-3 3.15e-2 0.64
MBNL1 Muscleblind like splicing regulator 1 1.73e-6 1.86e-2 1.34 5.91e-6 6.82e-3 0.73
Table 1. Genes significantly deregulated in both the Caco2 and SW480 cell lines under AURKA knockdown 
(n = 54). p-value, q-value and log2 fold change (FC) from the two differential mRNA expression analyses are 
shown for each gene ID. The Gene names are retrieved from Ensembl. The table is sorted on SW480 log2 FC. 
*Gene id and gene name are not available. The Ensembl id is provided as identifier. **FC = log2 fold change.
Figure 2. Significantly deregulated gene modules in SW480 (A) and Caco2 (B) derived from integrating 
p-values from differential mRNA expression analysis (DEA) upon downmodulation of AURKA and STRING 
protein-protein interaction network data using the Heinz algorithm. (A) and (B) Based on the chosen FDR 
threshold of 6.21e-4 for SW480 and 2.40e-4 for Caco2 in the Heinz analysis, round nodes are significant (p-value 
lower than the FDR threshold), and squared nodes are non-significant (p-value above the FDR threshold). The 
size of the nodes is based on the p-values from the DEA: a lower p-value corresponds to a bigger node. The 
colour of the nodes indicates the direction of the fold change with respect to AURKA downmodulation in the 
DEA. Red nodes are downregulated and blue nodes upregulated. The colour intensity of the nodes is correlated 
with the magnitude of the fold change, where the greatest intensities represent the highest absolute fold change. 
The nodes of the nine genes occurring in both modules are outlined in black and the direct edges between these 
are in bold. The nodes representing proteins in the Wnt or Ras-MAPK pathways have a black dot.
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interaction network. This analysis was repeated for each of the cell lines, SW480 and Caco2. We used a subset of 
the STRING PPI only consisting of the genes that were either significantly deregulated in the DEA or part of the 
most significantly deregulated module from the Heinz analysis. The shortest path between each of these genes 
to AURKA was determined for SW480 (Fig. 3B) and Caco2 (Fig. 3C). Some of these interactions are directly 
from AURKA to Wnt and Ras-MAPK genes, but most are indirectly via additional interactions outside Wnt or 
Ras-MAPK signalling. For both cell lines there were six such external ‘connecting genes’: LCK and PPP1CB in 
SW480, and ALB and CASK in Caco2, and four shared: UBE2D1, DICER1, CDK6 and RACGAP1. We propose 
that these genes could be important to explain the observed correlation between AURKA modulation and Wnt 
and Ras-MAPK activity.
Figure 3. Wnt and Ras-MAPK pathway genes and interacting genes with AURKA, significantly deregulated 
(DEA) or in the most significantly deregulated gene module (Heinz) in the two cell lines, SW480 and Caco2. 
(A) Overview of AURKA, the genes in the Wnt and Ras-MAPK pathways, and the genes connecting these, 
either significantly deregulated (DEA; q-value < 0.05, red for down and blue for upregulation) or found in the 
most significantly deregulated gene module (Heinz, grey edges) in the two cell lines. (B) and (C) Interactions 
between AURKA (top-middle, purple) and the Wnt and Ras-MAPK signalling genes (green shades) deduced 
together with additional ‘connecting genes’ (orange) using a shortest path analysis in SW480 (B) and Caco2 (C).
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TCGA CRC data analysis. The Wnt and Ras-MAPK pathway proteins and their molecular interactions with 
AURKA identified in this study are based on two CRC cell lines with 20q gain where AURKA is downmodulated. 
These results provide us with a better understanding of possible interconnections between AURKA and Wnt and 
Ras-MAPK signalling, however, to gain insight into the CRC progression it is necessary to study these genes from 
a cellular context that better represents the physiological environment. In CRC tissue samples where epithelial 
neoplastic cells interact with their tumour microenvironment the biology is more complex and heterogeneous 
than in isolated epithelial cancer cell lines.
We analysed publicly available CRC samples from TCGA (RNA-seq and somatic copy number aberration 
data) to see if we could recover the significantly deregulated genes from the CRC cell line DEA. Out of 330 
microsatellite stable tumour samples, 217 (65.76%) had AURKA copy number aberration, determined by a seg-
ment mean threshold of 0.4 in the somatic copy number aberration data (see Materials and Methods). DEA was 
performed between the AURKA-no-gain and AURKA-gain samples using the RNA-seq expression data. Note 
this atypical order of the sample groups (no-gain vs. gain instead of gain vs. no-gain) is to ensure proper com-
parison to the distinctive setup of the cell line experiments where AURKA is downmodulated (see Materials and 
Methods). AURKA was significantly deregulated (p-value = 1.62e-26), demonstrating the correlation between 
increased AURKA count and copy number gain. In total, 1308 genes were significantly deregulated in the AURKA 
no-gain samples with a significance threshold of the adjusted p-value less than 10−5, 751 up and 557 down 
(Supplementary Table S6). We then investigated the significance and directionality of the genes located on 20q. 
First, we retrieved the Ensembl ids for the genes located on 20q11-20q13.33 from BioMart. Second, we mapped 
these Ensembl ids to the Ensembl ids in the TCGA samples, which resulted in 316 genes. Out of these, 168 were 
significantly deregulated, 164 down and 4 up. Thus, 163 genes located on 20q11-20q13.33 are significantly dereg-
ulated in the same direction as AURKA (Supplementary Table S7).
We compared the significantly deregulated genes in the TCGA AURKA no-gain samples (n = 1308) to the sets 
of genes significantly deregulated in the SW480 (n = 292) and Caco2 (n = 154) DEA (described above). A minor 
overlap was found; only 24 genes were significantly deregulated in the TCGA and either of the cell lines (14 in 
SW480 and 13 in Caco2). Further, the majority of these genes were deregulated in opposite directions between 
the two different settings (see Supplementary Fig. S4).
Discussion
In this study we identified 20 Wnt and Ras-MAPK signalling genes and eight additional connecting genes that 
suggest possible mechanisms of interaction between AURKA and Wnt and Ras-MAPK signalling in a CRC cell 
line setting. We performed mRNA expression analysis on AURKA knockdown in two CRC cell lines, SW480 
and Caco2, and applied three main computational approaches to interpret this expression data. First, we applied 
straightforward gene-centric DEA determining significantly deregulated genes. Second, we applied the Heinz 
algorithm, an integrative network-aware analysis, using the expression data and the STRING PPI network data 
to determine significantly deregulated gene modules. Third, we applied a shortest path analysis determining con-
nections between AURKA and Wnt and Ras-MAPK signalling genes that were significantly deregulated in the 
first two analyses, DEA and Heinz. The DEA resulted in the largest set of genes, however it does not by itself reveal 
how their deregulation may be intertwined. The Heinz integrative analysis clearly revealed in an unbiased way the 
involvement of the Wnt and Ras-MAPK pathways, as well as indicated some plausible mechanisms of interaction 
between AURKA and both pathways. Finally, the shortest path analysis added 8 connecting genes that may be 
relevant to explain how AURKA modulation may affect the activity of these pathways, and thereby further induce 
proliferation in developing carcinoma cells.
In previous studies interactions between AURKA and Wnt signalling have been observed in gastric cancer 
cell lines18,19 and glioma-initiating cells20, and interactions between AURKA and Ras-MAPK signalling have been 
observed in kidney cells21, pancreatic cancer cells22 and multiple myeloma23. Thus the link between AURKA 
and Wnt and Ras-MAPK signalling is not new in general, but the specific proteins that are deregulated differ 
between the different cellular contexts. For instance, GSK3B and AXIN1 are two proteins deregulated by AURKA 
leading to stimulation of Wnt signalling in gastric cancer cell lines18,19 and glioma-initiating cells20, respectively. 
Activation of Ras-MAPK by AURKA has been attributed to interaction between AURKA and the H-RAS/Raf-1 
complex in kidney cells21. In our analysis, in the two CRC cell lines, SW480 and Caco2, differential expression of 
GSK3B, AXIN1 and HRAS, was not recovered, however, AXIN2 and KRAS, homologous of AXIN1 and HRAS, 
respectively, were recovered. Besides the differences in the cellular contexts, a plausible explanation for not recov-
ering GSK3B and AXIN1 in our analysis could be that GSK3B phosphorylation and AXIN1 binding to AURKA 
and β-catenin involve changes at the protein level, which would not be visible in our mRNA expression data. 
Another limitation of our experimental setup is that AURKA is the only gene that is downmodulated, whereas in 
an in vivo setting more genes on 20q are deregulated together with AURKA. One example is TPX2, which just as 
with AURKA is located on 20q, and implied to be involved with gain of 20q11, however, in our analysis TPX2 is 
not modulated.
Based on our analysis, the genes in the Wnt and Ras-MAPK pathways affected by AURKA downmodulation 
were mostly unique per cell line. In the Wnt pathway, only β-catenin was affected in both cell lines, and in the 
Ras-MAPK pathway, it was only KRAS. It should be noted, however, that these genes are at the core of their 
respective pathways, which suggests that in both cellular contexts, perturbing these pathways may be very impor-
tant. The molecular differences can be explained by the cause or the effect of the perturbations being dependent 
on the particular cellular context. On the other hand, the ‘connecting genes’ (connecting AURKA to the Wnt and 
Ras-MAPK signalling genes) were mostly similar between the cell lines (four out of six genes shared in both). 
While both SW480 and Caco2 are CRC cell lines with 20q gain, AURKA overexpression, and TP53 mutation, they 
also show differences. Firstly, the cell lines originate from different individuals, and therefore different germline 
variations. Secondly, the two cell lines have progressed to carcinomas independently. One specific difference is 
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that KRAS is mutated in SW480 but not in Caco225. However, their genetic differences are much more extensive 
than this (see DNA copy number profiles in Supplementary Fig. S1). Consequently, the underlying molecular 
biology of SW480 and Caco2 differs and they are therefore expected to respond differently to a perturbation such 
as AURKA downmodulation when looking at the expression of individual genes, although the overall changes 
in pathways could still be the same. For instance, KRAS is one of the most connected genes in both cell lines in 
our two network aware analyses (Figs 2 and 3), while at the same time the differentially expressed networks upon 
AURKA knockdown show different genes connected to KRAS in both cell lines. This could potentially be due to 
the different mutation status of KRAS between the cell lines. For instance, in the shortest path analysis (Fig. 3) 
KRAS is connected to AURKA and β-catenin in both cell lines. However, in SW480, where KRAS is mutated, 
KRAS in addition is connected to LCK, WNT5A, PPP3CA, JUN, and RAC2. Whereas, in Caco2, KRAS is in 
addition connected to FOS, AXIN2, and PRKCA.
The four consensus molecular subtypes (CMS) of colorectal cancer distinguish differences in signalling 
activities28. CMS2 and CMS4 are the most common chromosomal instable subtypes, both containing 20q gain, 
with CMS2 having a better prognosis than CMS4. CMS2 show increased proliferation, whereas CMS4 exhibit 
invasion. In a recent study29, they found that four genes were sufficient to predict CMS4: PDGFRA, PDGFRB, 
PDGFC and KIT. Interestingly, in the current study, PDGFRA (p-value = 1.28e-05) and the KIT ligand, KITLG 
(p-value = 3.19e-05), were significantly deregulated in Caco2, but not in SW480 (possibly explained by the differ-
ent genetic backgrounds). Thus upon AURKA downmodulation Caco2 resembles the CMS4 subtype, and it can 
be implied that Caco2 also displays the CMS4 phenotype, invasion.
The cell line results presented in this paper suggest possible interconnections between AURKA and Wnt and 
Ras-MAPK signalling. Analysis of the CRC tissue samples from the TCGA data provided results from a more 
appropriate cellular context for studying CRC progression. There was an overlap of 24 genes when comparing 
the significantly deregulated genes from the TCGA analysis and the cell line analyses. However, most of these 
overlapping significantly deregulated genes were deregulated in opposite directions between the two different 
settings (Supplementary Fig. S4). We should here take into account the big differences between these two settings. 
First, in the tissue samples from TCGA AURKA is gained as a result of gain in 20q, on which many more genes 
than only AURKA are located and affected (Supplementary Table S7). In the cell line experiments, however, only 
AURKA is downmodulated, whereas all the other genes on 20q have remained unchanged. Second, in a tumor, 
epithelial neoplastic cells interact with their tumor microenvironment. Thus, the tissue samples are much more 
complex than the cell lines, and most likely there would be feedback mechanisms active in this environment that 
do not operate in the isolated cell lines. Third, a tumor is very heterogeneous, whereas a cell line is much more 
homogeneous. Thus, the presence of multiple clones within a tumor might also mask the effect of AURKA gain 
present in a minority of the clones in the tumor. Thus, we believe that because of these big differences between the 
cell line and tissue settings, a gene that is deregulated in both cases does not necessarily have to be deregulated in 
the same direction, but the overlap of deregulated genes, and their pathways, provides a good starting point for 
further investigation of the mechanisms between AURKA and Wnt and Ras-MAPK signalling. At the same time, 
this also underlines the importance of cellular context when studying regulation of cancer.
In summary, gene-centric and network-aware analysis of CRC cell lines with AURKA knockdown shows that 
20 Wnt and Ras-MAPK signalling genes, occurring in connected PPI networks in two CRC cell lines, are signif-
icantly deregulated by AURKA. The responses in the Wnt and Ras-MAPK pathways were different in the two 
cell lines; only KRAS (Ras-MAPK) and β-catenin (Wnt) were deregulated in both. Further, in both cell lines 
four genes connected AURKA to the deregulated genes in the Wnt and Ras-MAPK pathways: CDK6, UBE2D1, 
DICER1 and RACGAP1. These results suggest possible genes and mechanisms for the interplay between AURKA 
and Wnt and Ras-MAPK signalling that are at the same time generic and unique between different CRC settings. 
Further investigation of the importance of Wnt and Ras-MAPK enhanced signalling by AURKA in CRC and 
the role of these genes for these interactions, will lead to a better understanding of the molecular mechanisms 
underlying CRC progression.
Materials and Methods
Cell culture and transfection with small interfering RNA (siRNA). SW480 cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Verviers, Belgium) containing 10% fetal bovine serum 
(FBS) (HyClone; Perbio Science, Etten-Leur, The Netherlands), and Caco2 cells were grown in RPMI 1640 
(Lonza) containing 20% FBS. Both cell culture media were supplemented with 2 mM L-glutamine, 100 IU/ml 
sodium penicillin (Astellas Pharma B.V., Leiderdorp, the Netherlands), and 100 mg/ml streptomycin 
(Fisiopharma, Palomonta (SA), Italy). Transfection with siRNA pools (SMARTpools) from Dharmacon 
(Lafayette, Colorado, USA) was performed 24 h after seeding according to the manufacturer’s recommendations. 
A final siRNA concentration of 30 nM was obtained using DharmaFECT3 reagent (1:1000 dilution) for both cell 
lines. A non-targeting control siRNA pool (Non-Targeting Pool 2; D-001206-14) was used as a negative control.
RNA isolation. Total RNA was isolated using TriZol reagent (Invitrogen, Breda, the Netherlands) and sub-
jected to purification using RNeasy Kit (Qiagen, Hilden, Germany). RNA concentrations and purities were 
measured on a Nanodrop ND-1000 spectrophotometer (Isogen, IJsselstein, the Netherlands). RNA quality was 
evaluated by generating an electropherogram on the Agilent Bioanalyzer 2100 using a RNA 6000 Nano-LabChip 
(Agilent Technologies, Santa Clara, CA, the Netherland). RNA integrity numbers (RIN) of >9.0 were considered 
as good quality RNA.
Microarray expression analyses. Microarray expression experiments were performed on 4 × 44 K 
Agilent expression arrays (Agilent 60-mer SurePrint technologies), as described before30. Two biological rep-
licates were performed for each siRNA experiment (both AURKA and non-targeting). Pre-processing and 
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differential expression analysis (DEA) was done using the R-Bioconductor packages Limma31 and SVA-combat32. 
In short, conventional background correction was applied, followed by within-array normalization using Loess. 
Subsequently, batch-effect removal was applied for the replicate experiments, after which between-array normal-
ization was done using the quantile method. The microarray data have been submitted to NCBI’s Gene Expression 
Omnibus (GEO) and are accessible through GEO Series accession number GSE108320. DEA between AURKA 
siRNA transfected cells and non-targeted siRNA control transfected cells was assessed by using linear modelling 
and empirical Bayes statistics. Finally, p-values were adjusted for multiple testing using conventional Benjamini 
Hochberg FDR correction. The threshold for significantly expressed genes was set at a q-value less than 0.05 and a 
fold change greater than 1.5 or less than −1.5. The significantly deregulated genes are available in Supplementary 
Table S1 for SW480 and Supplementary Table S2 for Caco2. GO enrichment analysis was performed using the 
‘Gene Ontology enRIchment anaLysis and visuaLizAtion tool’ (http://cbl-gorilla.cs.technion.ac.il/).
Probe ID mapping. The Agilent probe ids from the microarray expression experiments were mapped to 
their respective Ensembl ids and HGNC ids (when available) using BioMart mappings (‘Agilent WholeGenome 
4 × 44 k v1 probe’) downloaded from www.ensembl.org/biomart/martview/ (January 2017). Additional mapping 
of HGNC ids to Ensembl ids was done using mappings from the Agilent website http://www.chem.agilent.com/
cag/bsp/gene_lists.asp (Human Genome, Whole - Four-Plex, 44 K) (January 2017). We manually checked and 
mapped the significantly expressed genes for each cell line. Out of the 30,889 and 30,105 Agilent probe ids 8,270 
and 8,149 could not be mapped to Ensembl ids for Caco2 and SW480, respectively. Where the same Ensembl id 
was mapped to multiple Agilent probe ids, the Agilent probe id with the lowest p-value was chosen. This filtering 
step resulted in 24,589 and 24,088 probes whereof 16,319 and 15,939 has unique Ensembl ids for Caco2 and 
SW480, respectively.
Protein-protein interaction network. The Homo sapiens protein-protein interaction (PPI) network used 
in this analysis was retrieved from the STRING database (medium confidence: 0.400)27 (downloaded: January 
2017). The proteins were mapped to Ensembl ids using BioMart mappings (as described in the previous section). 
Self- and duplicate interactions were removed. The network consisted of 680,790 PPIs.
To describe the nodes (genes) and edges (interactions), one node-file and one edge-file were constructed for 
each cell line, SW480 and Caco2, based on the intersection of nodes (Ensembl ids) in the AURKA knockdown 
DEA data and the STRING PPI data. The edges-files consisted of two columns with Ensembl ids representing the 
two interacting proteins. The node-file consisted of three columns: nodes (Ensembl id), p-values, and log2 fold 
change. The Caco2 edge-file consisted of 456,552 edges, and the SW480 edge-file consisted of 437,865 edges. The 
Caco2 node-file consisted of 12,249 nodes, while that for SW480 consisted of 12,082 nodes.
Identification of the most significantly deregulated gene modules. The Heinz algorithm26 was 
applied to determine the most significantly deregulated gene module (sets of genes connected in the PPI network) 
for each cell line, SW480 and Caco2, using the constructed edge- and node-files. Each node in the network was 
assigned a weight reflecting its p-value from the DEA. A beta-uniform mixture model was fitted to the p-value 
distribution determining its parameters: the shape parameter, α, and the mixture parameter, λ33. The α parameter 
was 0.342 for SW480 and 0.329 for Caco2. Due to the high amount of low p-values, the λ parameter was approxi-
mated 0.0 in both cell lines. Before calculating the weights of the nodes we set the λ parameters to 0.1, which still 
gave a very reasonable fit. The Heinz algorithm then assigned weights to the nodes using the λ and α parameters, 
the p-values and a false-discovery rate (FDR) threshold. Positive weights were given to nodes with a p-value 
lower than the FDR threshold, whereas negative weights were given to nodes with a p-value greater than the FDR 
threshold. The FDR threshold for SW480 was 6.21e-4 corresponding to a p-value of 4.46e-5. The FDR threshold 
for Caco2 was 2.40e-4 corresponding to a p-value of 1.37e-5. The Heinz algorithm subsequently calculated the 
maximum-scoring subnetwork of the STRING PPI network that represents the most significantly deregulated 
gene module. The genes in these modules and their p-values and log2 fold changes are available in Supplementary 
Table S3 for SW480 and Supplementary Table S4 for Caco2.
Since the FDR threshold has an influence on how many nodes are assigned positive weights, it also has an 
influence on the size of the significantly deregulated gene module. We selected the FDR thresholds so that 50 
genes had a positive weight for each cell line. These thresholds are a conservative choice to generate focus on the 
part of the network that shows the strongest deregulation. This means that genes with p-values just above the 
threshold may still be significantly deregulated. The resulting modules selected by Heinz are not very sensitive to 
the FDR setting, simply said the modules just incrementally grow or shrink, as the threshold is adapted.
Determining Wnt and Ras-MAPK signalling genes. To define which genes are in the Wnt and 
Ras-MAPK pathways we downloaded the gene lists of the ‘Wnt signalling pathway’, ‘MAPK signalling pathway’ 
and ‘Ras signalling pathway’ from the KEGG database (January 2017)34. These genes were used to annotate Wnt 
and Ras-MAPK signalling genes in the results.
Shortest path analysis. To find possible connections between AURKA and the signalling pathways of 
interest, we performed a shortest-path analysis. The shortest path is defined as the minimum number of edges 
required to travel from one node in the PPI graph to another. First, we reduced the STRING PPI network to a 
subnetwork only consisting of the significantly deregulated genes determined by the DEA and the genes located 
in the most significantly deregulated gene module in the Heinz analysis. We then applied the Python package 
NetworkX to compute all the shortest paths between AURKA and the Wnt and Ras-MAPK signalling genes, 
where the edges were unweighted.
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TCGA CRC data analysis. To compare the effect of AURKA on Wnt and Ras-MAPK signalling in CRC 
tissue data to our CRC cell line results we analysed the TCGA COADREAD5 RNA-seq and somatic copy number 
aberration data for 330 microsatellite stable tumour samples retrieved from Firehose (March 2017). First, the 
samples were labelled by AURKA-gain and AURKA-no-gain based on the copy number aberration data in the 
genome region 54,944,445-54,967,393 (genome build 19) encoding the AURKA gene. Samples with a segment 
mean greater than or equal to 0.4 were labelled AURKA-gain, whereas samples with a segment mean less than 
0.4 were labelled AURKA-no-gain (Supplementary Table S5). The segment mean is the average of the tumour 
versus normal intensity log2 ratio, thereby describing the copy number aberrations. We selected the threshold 
of 0.4 following the assumption that the gain of AURKA also increases its expression (Supplementary Fig. S2). 
Second, DEA was performed between the AURKA-no-gain and AURKA-gain samples. The atypical choice of per-
forming a no-gain vs. gain comparison (instead of gain vs. no-gain) is because of the distinctive setup of the cell 
line experiments themselves, where the non-perturbed cell lines have AURKA gain and the perturbed cell lines 
have an AURKA downmodulation (no-gain). Significantly expressed genes based on the DEA were determined 
at an adjusted p-value less than 10−5 (Supplementary Fig. S3). The significantly deregulated genes are available 
in Supplementary Table S6. We then investigated the significance and directionality of the genes located on 20q. 
First, we retrieved the Ensembl ids for the genes located on 20q11-20q13.33 from BioMart. Second, we mapped 
these Ensembl ids to the Ensembl ids in the TCGA samples. The TCGA DEA result for these genes is available in 
Supplementary Table S7. Finally, we determined the overlap of significantly deregulated genes between the TCGA 
DEA and the DEA of SW480 and Caco2 (Supplementary Fig. S4).
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